Plasma Cell Disorders Clinical Trial
Official title:
Registry of Patients With Plasma Cell Disorders
The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are: - The incidence of plasma cell disorders both before and after malignancy - Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM) - Progression free survival (PFS) - overall survival - factors influencing overall survival, progression-free survival, and time to progression - Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients. - genetic characteristics of plasma cell disorder - cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02566265 -
Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients
|
Phase 2 | |
| Completed |
NCT01362985 -
Analysis of Data Collected in the European Group for Blood and Marrow Transplantation (EBMT) Registry for Off-Label Transplant Use of Plerixafor
|
Phase 4 | |
| Recruiting |
NCT06252948 -
Gut Microbiome Studies in Patients With POEMS Syndrome and Other Plasma Cell Disorders
|